CorMedix (NASDAQ:CRMD) Shares Gap Down Following Analyst Downgrade

CorMedix Inc (NASDAQ:CRMD) gapped down prior to trading on Thursday after Needham & Company LLC lowered their price target on the stock from $16.00 to $15.00. The stock had previously closed at $11.17, but opened at $8.73. Needham & Company LLC currently has a buy rating on the stock. CorMedix shares last traded at $8.0490, with a volume of 5,682,994 shares trading hands.

Several other research analysts have also issued reports on the company. Wall Street Zen lowered CorMedix from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. HC Wainwright boosted their price objective on shares of CorMedix from $17.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, November 13th. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of CorMedix in a research report on Thursday. Royal Bank Of Canada reissued an “outperform” rating and issued a $22.00 price target (up previously from $21.00) on shares of CorMedix in a report on Tuesday, October 21st. Finally, Truist Financial set a $16.00 price objective on CorMedix in a research note on Thursday. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, CorMedix has a consensus rating of “Buy” and an average target price of $17.86.

Insider Buying and Selling at CorMedix

In related news, Director Myron Kaplan acquired 25,000 shares of the firm’s stock in a transaction dated Thursday, October 23rd. The stock was bought at an average price of $11.02 per share, for a total transaction of $275,500.00. Following the acquisition, the director directly owned 201,034 shares of the company’s stock, valued at approximately $2,215,394.68. The trade was a 14.20% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven W. Lefkowitz sold 40,000 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $11.88, for a total transaction of $475,200.00. Following the completion of the transaction, the director directly owned 80,498 shares of the company’s stock, valued at $956,316.24. This represents a 33.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 90,000 shares of company stock worth $1,095,200 in the last three months. 3.10% of the stock is currently owned by company insiders.

Key CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Analyst support remains: D. Boral Capital reaffirmed a “buy” rating with a $14 target, and Needham maintained a buy rating despite trimming its target from $16 to $15 — these endorsements help provide demand support for the shares. Analyst notes
• Positive Sentiment: Management continuity: CEO Joseph Todisco signed an extended employment contract and will add the Chairman role while the prior chair moves to Lead Independent Director — the move signals board-level continuity during the reset. Leadership update
• Neutral Sentiment: Investor outreach / visibility: Management will present a corporate overview at the J.P. Morgan Healthcare Conference (Jan 12), which could provide additional color and catalyze trading flows depending on guidance detail and Q&A. JPM presentation
• Neutral Sentiment: Valuation / bullish commentary: Coverage pieces (Zacks, Yahoo analysis) argue the stock may be undervalued or worth reassessing after the recent operational reset; these are watch items but not immediate catalysts. Zacks coverage
• Negative Sentiment: Material FY-2026 guidance reset: Management trimmed FY-2026 revenue guidance to $300–$320M versus consensus (~$445M), creating a large miss expectation and driving heavy selling pressure. Guidance cut article
• Negative Sentiment: Preliminary results and reduced outlook triggered downside: Q4/FY-2025 preliminary numbers were reported but the updated FY-2026 revenue range and related messaging prompted immediate negative investor reaction and headlines about a stock crash. Preliminary results
• Negative Sentiment: Reimbursement risk flagged: Analysis notes emerging CMS reimbursement headwinds that could pressure future revenue realization and margins — this is a structural risk that could sustain downward pressure if unresolved. CMS reimbursement analysis

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CRMD. Ameritas Investment Partners Inc. raised its holdings in CorMedix by 17.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock valued at $81,000 after acquiring an additional 998 shares during the period. Russell Investments Group Ltd. lifted its holdings in CorMedix by 22.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company’s stock worth $81,000 after purchasing an additional 1,190 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in CorMedix by 11.9% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 13,622 shares of the company’s stock worth $168,000 after purchasing an additional 1,451 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of CorMedix by 5.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,114 shares of the company’s stock valued at $338,000 after acquiring an additional 1,478 shares during the period. Finally, Palisades Investment Partners LLC boosted its holdings in CorMedix by 0.3% in the 3rd quarter. Palisades Investment Partners LLC now owns 564,106 shares of the company’s stock valued at $6,561,000 after purchasing an additional 1,579 shares during the period. 34.18% of the stock is owned by institutional investors and hedge funds.

CorMedix Stock Up 1.6%

The stock’s fifty day simple moving average is $10.96 and its 200-day simple moving average is $11.62. The stock has a market cap of $601.17 million, a P/E ratio of 3.70 and a beta of 1.36. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.73 and a current ratio of 1.94.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.78. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The firm had revenue of $104.28 million during the quarter, compared to analysts’ expectations of $65.63 million. During the same period in the previous year, the firm earned ($0.05) EPS. The company’s quarterly revenue was up 810.2% compared to the same quarter last year. As a group, research analysts forecast that CorMedix Inc will post -0.32 earnings per share for the current fiscal year.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.